Ciclosporine collyrium is used in the treatment of severe keratitis in adult patients with xerophthalmia who did not improve despite the treatment with eyedrops. The presentation currently commercialised has a concentration of 0.1% although there is also a 0.05% compounding.

The purpose is to evaluate the safety of 0.1% ciclosporine collyrium assessing the rate of patients who do not tolerate this presentation and its causes.

MATERIAL AND METHODS

- This is a retrospective observational study.
- It has been realised in a model hospital in this area.
- All patients treated with ciclosporine collyrium between January and September of 2021 were included.
- Demographic (sex and age) data were collected from the computerised clinic history.
- A questionnaire was made for the clinic interview of the external patients who had adverse reactions after the treatment with 0.1% ciclosporine collyrium thus they had to switch to the 0.05% formula. In this questionnaire the reason of the switch, kind of adverse reaction, severity and time of appearance (immediate/late) were included.

RESULTS

11.67% of the patients suffered some adverse reaction which forced to switch the 0.1% ciclosporine presentation to the 0.05% ciclosporine Pharmacy Unit made compounding. The switch to our compounding (0.05% ciclosporine collyrium formula) were well tolerated in 100% of the cases.

CONCLUSION

The 0.1% ciclosporine presentation is safe thus it was well tolerated in most of our patients, just 11.67% had some adverse reaction. Moreover these patients did not suffer any adverse reaction with our free preservative 0.05% ciclosporine Pharmacy Unit made compounding, thus we cannot know if this reaction is due to the ciclosporine bigger concentration or some of its excipients, further research is needed.